Goldman Sachs Group Inc. trimmed its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 24.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 286,278 shares of the company's stock after selling 94,069 shares during the period. Goldman Sachs Group Inc. owned approximately 0.48% of Janux Therapeutics worth $7,730,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after acquiring an additional 1,574 shares during the period. US Bancorp DE grew its position in Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after acquiring an additional 1,658 shares during the period. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics in the fourth quarter worth approximately $59,000. FNY Investment Advisers LLC grew its position in Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after acquiring an additional 2,425 shares during the period. Finally, KBC Group NV purchased a new position in Janux Therapeutics in the first quarter worth approximately $66,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.
Janux Therapeutics Stock Performance
Shares of JANX stock traded up $0.01 during mid-day trading on Friday, hitting $24.41. 233,937 shares of the stock were exchanged, compared to its average volume of 901,599. The stock's fifty day simple moving average is $24.48 and its two-hundred day simple moving average is $26.14. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -13.55 and a beta of 2.84. Janux Therapeutics, Inc. has a 12-month low of $21.97 and a 12-month high of $71.71.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). On average, research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on JANX. Stifel Nicolaus reiterated a "buy" rating and issued a $45.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Piper Sandler began coverage on Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 price target for the company. Barclays began coverage on Janux Therapeutics in a research report on Wednesday. They set an "overweight" rating and a $47.00 price target for the company. Guggenheim began coverage on Janux Therapeutics in a research report on Wednesday, September 3rd. They set a "buy" rating and a $72.00 price target for the company. Finally, Truist Financial began coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They set a "buy" rating and a $100.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $78.31.
Check Out Our Latest Stock Analysis on JANX
About Janux Therapeutics
(
Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
See Also
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
